Financials TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
13.47 USD -3.16% Intraday chart for TG Therapeutics, Inc. -2.25% -21.14%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,089 6,703 2,488 1,584 2,416 1,952 - -
Enterprise Value (EV) 1 1,089 6,179 2,257 1,494 2,299 1,900 1,835 1,691
P/E ratio -5.66 x -21.5 x -7.22 x -8.1 x 190 x -127 x 25.9 x 9.94 x
Yield - - - - - - - -
Capitalization / Revenue 7,164 x 44,097 x 372 x 569 x 10.3 x 7.29 x 4.69 x 3.3 x
EV / Revenue 7,164 x 40,652 x 337 x 536 x 9.84 x 7.1 x 4.41 x 2.86 x
EV / EBITDA - - -6.55 x -7.76 x 110 x 444 x 31.5 x 24.4 x
EV / FCF -8.13 x -28.8 x -7.62 x -8.48 x -73.2 x -808 x 11.8 x 5.17 x
FCF Yield -12.3% -3.48% -13.1% -11.8% -1.37% -0.12% 8.46% 19.3%
Price to Book - 14.1 x 11.5 x 27.3 x 15.8 x 9.83 x 10.5 x 4.79 x
Nbr of stocks (in thousands) 98,104 128,848 130,950 133,915 141,455 144,904 - -
Reference price 2 11.10 52.02 19.00 11.83 17.08 13.47 13.47 13.47
Announcement Date 3/2/20 3/1/21 3/1/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.152 0.152 6.689 2.785 233.7 267.6 416.4 591.8
EBITDA 1 - - -344.5 -192.5 20.84 4.283 58.21 69.39
EBIT 1 -169.1 -273.6 -344.8 -192.8 20.63 -11.44 82.41 223.2
Operating Margin -111,220.39% -179,996.05% -5,154.28% -6,924.2% 8.83% -4.27% 19.79% 37.72%
Earnings before Tax (EBT) 1 -172.9 -279.4 -348.1 -198.3 13.06 -14.05 97.29 257.9
Net income 1 -172.9 -279.4 -348.1 -198.3 12.67 -14.41 83.03 216.7
Net margin -113,730.92% -183,803.29% -5,204.08% -7,121.54% 5.42% -5.39% 19.94% 36.61%
EPS 2 -1.960 -2.420 -2.630 -1.460 0.0900 -0.1057 0.5200 1.355
Free Cash Flow 1 -133.9 -214.9 -296 -176.2 -31.41 -2.35 155.2 327
FCF margin -88,097.37% -141,357.89% -4,425.7% -6,326.18% -13.44% -0.88% 37.27% 55.26%
FCF Conversion (EBITDA) - - - - - - 266.63% 471.31%
FCF Conversion (Net income) - - - - - - 186.93% 150.94%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/2/20 3/1/21 3/1/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 2.03 2.321 2.016 0.594 0.094 0.08 7.803 16.07 165.8 43.97 54.58 56.89 66.31 78.79
EBITDA 1 -85.05 -92.87 -66.8 -38.86 - -51.99 -36.92 -44.64 114.9 -12.45 - -6 -5 3
EBIT 1 -85.13 -92.95 -66.87 -38.94 -34.96 -52.06 -36.99 -44.67 114.8 -12.48 -6.134 -9.597 -5.576 1.023
Operating Margin -4,193.5% -4,004.61% -3,317.06% -6,555.72% -37,194.68% -65,077.5% -474.07% -277.93% 69.22% -28.39% -11.24% -16.87% -8.41% 1.3%
Earnings before Tax (EBT) 1 -85.64 -93.34 -69.01 -40.51 -35.82 -52.99 -39.23 -47.61 113.9 -14.03 -4.31 -10.86 -3.745 0.1728
Net income 1 -85.64 -93.34 -69.01 -40.51 -35.82 -52.99 -39.23 -47.61 113.9 -14.42 -6.425 -10.86 -7.188 -0.303
Net margin -4,218.57% -4,021.46% -3,423.26% -6,819.87% -38,104.26% -66,242.5% -502.78% -296.19% 68.71% -32.79% -11.77% -19.08% -10.84% -0.38%
EPS 2 -0.6500 -0.7000 -0.5100 -0.3000 -0.2600 -0.3900 -0.2800 -0.3400 0.7300 -0.1000 -0.0433 -0.0733 -0.0500 -0.005000
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/4/21 3/1/22 5/10/22 8/8/22 11/9/22 2/28/23 5/1/23 8/1/23 11/1/23 2/28/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 524 231 90.5 117 51.9 116 261
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -134 -215 -296 -176 -31.4 -2.35 155 327
ROE (net income / shareholders' equity) - -100% -92% -134% 11.6% 6.55% 15.3% 54%
ROA (Net income/ Total Assets) - -70.8% -69.3% -69.2% 4.84% -3% 7.2% 29.5%
Assets 1 - 394.3 502.6 286.6 261.6 480.4 1,153 734.5
Book Value Per Share 2 - 3.690 1.660 0.4300 1.080 1.370 1.280 2.810
Cash Flow per Share 2 - - - -1.300 -0.2100 -0.2400 0.8800 -
Capex 1 0.13 0.36 0.4 0.01 - 16.1 28.1 41.4
Capex / Sales 86.18% 234.87% 5.99% 0.5% - 6% 6.75% 7%
Announcement Date 3/2/20 3/1/21 3/1/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.47 USD
Average target price
29.75 USD
Spread / Average Target
+120.86%
Consensus
  1. Stock Market
  2. Equities
  3. TGTX Stock
  4. Financials TG Therapeutics, Inc.